5 completed, 1 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow etaracizumab: new trials by email Literature Review of etaracizumab trials Research Report on etaracizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer etaracizumab, bevacizumab - Recurrent Renal Cell Cancer, Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2008-06-01 | 2014-05-15 |
| Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma MEDI-522 - Malignant Melanoma | Phase 1 | Completed | MedImmune LLC | 18 | 2005-05-01 | 2012-03-14 |
| Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma etaracizumab - Lymphoma, Small Intestine Cancer | Phase 1 | Completed | University of Wisconsin, Madison | 2002-10-01 | 2019-12-13 | |
| Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer MEDI-522 - Cancer | Phase 1 / Phase 2 | Completed | MedImmune LLC | 17 | 2001-07-01 | 2008-05-29 |
| Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer etaracizumab - Colorectal Cancer | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-06-01 | 2013-06-05 | |
| Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors MEDI-522 - Cancer | Phase 1 | Completed | MedImmune LLC | 24 | 2001-03-01 | 2009-01-29 |
Neoplasms (2) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Large-Cell, Immunoblastic (1)
MedImmune LLC (3) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Wisconsin, Madison (1)
United States (5) · France (1)
Christopher Ryan (1) · Douglas McNeel, MD, PhD (1) · Krista Arbaugh, Dir., Clinical Ops (1) · Leonard B. Saltz, MD (1) · Luz Hammershaimb, MD (1) · Stergios Moschos, MD (1)
P30CA014520 (1), U10CA032102 (1)